Sort   by:  
 Page size 
ProteomicsCDC14B interactome - The proteomic approach aimed at the identification of interaction partners for the human dual phosphatase and tumor suppressor CDC14B by Co-inmunoprecipitation (Co-IP) experiments. In this approach, CDC14B interactomes from unsynchronized and G2/M enriched cells were compared semi-quantitatively based on spectral counting. This approach yielded the deubiquitylase USP9X as a G2/M-specific CDC14B interactor which has been confirmed by Western-blot (WB).
The proteomic approach aimed at the identification of interaction partners for the human dual phosphatase and tumor suppressor CDC14B by Co-inmunoprecipitation (Co-IP) experiments. In this approach, CDC14B interactomes from unsynchronized and G2/M enriched cells were compared semi-quantitatively bas...
ORGANISM(S): Homo sapiens (Human) 
2020-03-25 | PXD012732 | Pride
Usp9x Cdc14b 
ProteomicsUSP9X phosphopeptide mapping - We previously identified the deubiquitylase USP9X as a G2/M-specific CDC14B interactor (PXD012732). The functional connection of these proteins has been further investigated by a quantitative comparison of USP9X phosphorylation in WT vs CDC14B-overexpressing HEK 293Tcells (ATCC® CRL-3216™). The approach identified USP9X serine 2563 as a specific CDC14B target. Phosphorylation at USP9XS2563 has been confirmed by in-house phosphospecific antibodies.
We previously identified the deubiquitylase USP9X as a G2/M-specific CDC14B interactor (PXD012732). The functional connection of these proteins has been further investigated by a quantitative comparison of USP9X phosphorylation in WT vs CDC14B-overexpressing HEK 293Tcells (ATCC® CRL-3216™). The appr...
ORGANISM(S): Homo sapiens (Human) 
2020-03-25 | PXD012733 | Pride
Cdc14b Usp9x 
ProteomicsMapping of TDP-43 ubiquitination and acetylation sites
TAR DNA binding protein of 43 kDa (TDP-43) forms aggregates in neurodegenerative diseases, particularly certain forms of frontotemporal dementia and amyotrophic lateral sclerosis. Pathological modifications of TDP-43 include proteolytic fragmentation, phosphorylation, and ubiquitinylation. In this s...
ORGANISM(S): Homo sapiens (Human) 
2022-04-01 | PXD030170 | Pride
Acetylation Ubiquitination Tdp-43 
ProteomicsMapping of nanobody binding sites on human LRRK2 by CX-MS
As part of an in-depth characterization of nanobodies directed against the human Leucine-rich repeat kinase 2 (LRRK2), epitopes of the nanobodies bound to LRRK2 were mapped by chemical crosslinking combined with mass spectrometry using the CID-cleavable crosslinker disuccinimidyl sulfoxide (DSSO).
ORGANISM(S): Homo sapiens (Human) 
2022-02-27 | PXD030063 | Pride
Cl-ms Lrrk2 Dsso Nanobodies Cx-ms Crosslinking Cid-cleavable 
ProteomicsAnalysis of Rab29 co-expression on the LRRK2 proximity proteome
Rab29 has been shown to bind the LRRK2 N-terminal Armadillo domain in µM affinity and act as upstream-effector localizing LRRK2 to endosomal membranes/ lysosomes. To determine the Rab29-dependent proximity proteome of the Parkinson’s protein LRRK2, three different BioIDapproaches have been applied. ...
ORGANISM(S): Homo sapiens (Human) 
2026-05-19 | PXD048808 | Pride
ProteomicsAnalysis of LRRK2 proximity proteome using BioID
To determine the proximity proteome of the Parkinson’s protein LRRK2, three different BioID approaches have been applied. Besides the original BirA-based BioID tag (BioID1), we have generated datasets using BioID2 and miniTurbo (mT), a truncated version of the TurboID tag.
ORGANISM(S): Homo sapiens (Human) 
2026-05-19 | PXD048832 | Pride
ProteomicsEffect of type I and type II kinase inhibitors on the LRRK2 proximity proteome
Type I and type II inhibitors have been demonstrated to stabilize LRRK2 either in an active or inactive kinase conformation. Furthermore, one type I inhibitors show a marked reduction in LRRK2 N-terminal phosphorylation on Serine 910 and 935. In this study, we generated comparative proximity proteom...
ORGANISM(S): Homo sapiens (Human) 
2026-05-19 | PXD048806 | Pride
GenomicsGenomes of Relapsing Neuroblastoma
Neuroblastoma is a malignancy of the developing sympathetic nervous system that is often lethal when relapse occurs, but the molecular mechanisms behind this process are poorly defined. We here used whole-exome sequencing, mRNA expression, array CGH and DNA methylation analysis to holistically chara...
EGAS00001001387 | EGA
Genomicsena-DATASET-UKEssen-09-09-2015-10:54:33:815-144 - samples
In this dataset, 16 trios- primary tumor, relapse and corresponding normals- for patients with neuroblastoma are provided. For one patient, more than one relapse was available for the analyses.
EGAD00001001607 | EGA
GenomicsRelapsed and Primary Neuroblastoma DAC
Data Access Committee EGAC00001000373
EGAC00001000373 | EGA
Sort   by:  
 Page size